Literature DB >> 29502255

Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.

Véronique Sgambato1, Léon Tremblay2.   

Abstract

The MPTP monkey model of Parkinson's disease (PD) has allowed huge advances regarding the understanding of the pathological mechanisms of PD and L-DOPA-induced adverse effects. Among the main findings were the imbalance between the efferent striatal pathways in opposite directions between the hypokinetic and hyperkinetic states of PD. In both normal and parkinsonian monkeys, the combination of behavioral and anatomical studies has allowed the deciphering of the cortico-basal ganglia circuits involved in both movement and behavioral disorders. A major breakthrough has then been made regarding the hypothesis of the involvement of serotonergic fibers in the conversion of L-DOPA to dopamine when dopaminergic neurons are dying and to release it, in an uncontrolled manner, as serotonergic neurons are deprived from the machinery required for buffering dopamine from the synaptic cleft. The crucial involvement of serotonergic fibers underlying L-DOPA-induced dyskinesia (LID) has been demonstrated in both rodent and monkey models of PD, in which dyskinesia induced by L-DOPA is abolished following lesion of the serotonergic system. Moreover, the role of serotonergic fibers goes well beyond dyskinesia, as lesioning of such serotonergic fibers by MDMA in the monkey also decreased other L-DOPA-induced adverse effects such as impulsive compulsive behaviors and visual hallucinations. The same pathological mechanism, i.e., an imbalance between serotonin and dopamine terminals may, therefore, favor L-DOPA-induced adverse effects according to the basal ganglia territory it inhabits. Further non-human primate studies will be needed to demonstrate the role of such a pathological mechanism in both movement and behavioral disorders driven by L-DOPA therapy but also to determine the causal link between serotonin lesions and the expression of non-motor symptoms like apathy, depression and anxiety, frequently observed in PD patients.

Entities:  

Keywords:  Basal ganglia; Dyskinesia; Impulse control disorders; Levodopa; Monkey; Serotonin

Mesh:

Year:  2018        PMID: 29502255     DOI: 10.1007/s00702-018-1871-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  103 in total

1.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate.

Authors:  B Gough; S F Ali; W Slikker; R R Holson
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

2.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.

Authors:  J S Schneider; A Pope-Coleman
Journal:  Neurodegeneration       Date:  1995-09

4.  Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.

Authors:  M Filion; L Tremblay; P J Bédard
Journal:  Brain Res       Date:  1991-04-26       Impact factor: 3.252

Review 5.  Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.

Authors:  Véronique Sgambato-Faure; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2017-02-07       Impact factor: 3.575

Review 6.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

7.  Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum.

Authors:  M Matsumura; L Tremblay; H Richard; M Filion
Journal:  Neuroscience       Date:  1995-03       Impact factor: 3.590

8.  Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.

Authors:  Andreas-Antonios Roussakis; Marios Politis; David Towey; Paola Piccini
Journal:  Neurology       Date:  2016-02-26       Impact factor: 9.910

Review 9.  Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations.

Authors:  Manolo Carta; Elisabetta Tronci
Journal:  Front Neurol       Date:  2014-05-20       Impact factor: 4.003

Review 10.  Serotonin in Parkinson's disease.

Authors:  Marios Politis; Flavia Niccolini
Journal:  Behav Brain Res       Date:  2014-07-31       Impact factor: 3.332

View more
  3 in total

Review 1.  Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

Authors:  Gregory M Pontone; Nadeeka Dissanayka; Liana Apostolova; Richard G Brown; Roseanne Dobkin; Kathy Dujardin; Joseph H Friedman; Albert F G Leentjens; Eric J Lenze; Laura Marsh; Lynda Mari; Oury Monchi; Irene H Richard; Anette Schrag; Antonio P Strafella; Beth Vernaleo; Daniel Weintraub; Zoltan Mari
Journal:  NPJ Parkinsons Dis       Date:  2019-12-11

Review 2.  Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

Authors:  Kathy Dujardin; Véronique Sgambato
Journal:  Front Neurosci       Date:  2020-01-29       Impact factor: 4.677

3.  The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.

Authors:  Feras Altwal; Connor Moon; Anthony R West; Heinz Steiner
Journal:  Cells       Date:  2020-10-09       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.